In the Trump administration’s program “MFN” means the U.S. price for a branded drug is set to match the lowest price that manufacturers charge for that same product in other developed countries (the “most‑favored‑nation” price). The May 12, 2025 Executive Order directs HHS and related agencies to identify MFN price targets and to press manufacturers to sell to U.S. patients at those prices; it does not publish a single, detailed formula (e.g., exact country list, net vs. list price adjustments, or currency-exchange method) — those specifics are left to agencies and to the manufacturer agreements or any future rulemaking.
The White House fact sheet says additional drugs from other companies that have signed MFN deals will be added “in the coming months,” but it does not list which specific products or manufacturers beyond the initial five (AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, Pfizer). No public, comprehensive list of future companies/products has been published yet.
The White House says patients with valid prescriptions can access savings via coupons printable or downloadable from TrumpRx.gov or through manufacturer channels integrated into the site. Acceptance at pharmacies and by pharmacy benefit managers (PBMs) depends on each manufacturer’s program and pharmacy agreements; the fact sheet does not guarantee universal acceptance by all pharmacies or PBMs.
HHS (including CMS and FDA components), the Office of the U.S. Trade Representative and the Department of Commerce are named in the Executive Order and White House materials as responsible for establishing MFN targets, negotiating/overseeing deals, and related actions; the White House fact sheet also indicates those agencies plus USTR and Commerce announced the U.K. agreement. Operational management of TrumpRx.gov is described as an Administration initiative but the fact sheet does not publish a detailed agency operations chart.
The fact sheet targets direct-to-consumer cash purchases through TrumpRx.gov; it does not say MFN prices will automatically change cost‑sharing under Medicare, Medicaid, or private insurance. Insured patients’ copays and coinsurance typically depend on their plan’s benefit design and whether the plan or PBM recognizes the coupon or price; the White House did not state that MFN rates will be applied to patients’ insurer cost‑sharing or to government program reimbursement formulas.
The Dec. 1, 2025 announcement by USTR, Commerce, and HHS described an agreement with the U.K. intended to raise the net price of new prescription drugs in the U.K. by about 25% so that U.K. prices are closer to U.S. levels; the White House frames this as using trade and diplomatic leverage to reduce ‘foreign freeloading.’ Public statements say the agencies negotiated with U.K. counterparts and drug manufacturers, but the fact sheet and agency notices give few public details about negotiation mechanics, specific concessions, or legal instruments used.